Trega Biosciences Announces Strategic Focus on Information-Based Products
SAN DIEGO, Feb. 11 /PRNewswire/ -- Trega Biosciences, Inc. (Nasdaq: TRGA) today announced that it is implementing certain initiatives designed to better focus its activities on the continuing development of products from its iDiscovery(TM) technologies. These products include its information-rich Chem.Folio(R) combinatorial libraries for screening against biological targets and its IDEA(TM) predictive models for the prediction and selection of compounds with essential drug-like characteristics for further development. Trega's iDiscovery technologies are intended to increase the chance of success and speed the pharmaceutical discovery and development process.
Consistent with this strategic focus, Trega has decided that it will no longer support in-house drug discovery that is not funded by a collaborator. Trega is currently carrying out a collaborative program in the area of diabetes, obesity, and syndrome X, funded by Novartis. The Company is seeking funded relationships for its other programs.
Trega Biosciences is an information-driven company focused on accelerating drug discovery from disease targets to clinical candidates through its iDiscovery(TM) technologies comprised of small molecule combinatorial chemistry, high throughput screens and predictive models to rapidly create novel drug candidates having greater chances of clinical success. Trega's iDiscovery technologies span the drug discovery process, beginning with synthesizing novel compounds to providing uniquely qualified drug leads to the pharmaceutical and life-science industries.
Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including whether any collaboration will be successful, any additional collaborations or alliances will be agreed to, formed or expanded, whether further Chem.Folio(R) libraries can be successfully developed and sold, whether the IDEA(TM) models can be successfully developed and commercialized, whether regulatory approvals can be obtained for products discovered and developed, if any, the impact of competitive products and pricing, whether any other corporate collaborations or alliances will be successful, and other risks detailed from time to time in Trega's Securities and Exchange Commission filings. These forward-looking statements represent Trega's judgment as of the date of this release. Actual results may differ materially from those projected. Trega disclaims, however, any intent or obligation to update these forward-looking statements.
For copies of press releases and additional information, please consult Trega's web site at trega.com or by PR Newswire's fax-on-demand service at 1-800-758-5804, extension 374050.
SOURCE Trega Biosciences, Inc.
CO: Trega Biosciences, Inc.
ST: California
IN: BIO MTC
SU:
02/11/2000 07:00 EST prnewswire.com |
